


Patient Perspectives: LIVING WITH IBS IN A PANDEMIC

Salix Pharmaceuticals, in partnership with The Fairleigh Dickinson University Poll, surveyed nearly 700 people living with irritable bowel syndrome in the United States to gain insight on the impact of the COVID-19 pandemic.

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder.





SINCE THE COVID-19 PANDEMIC BEGAN, RESPONDENTS REPORTED




*Respondents were also asked about Water Intake, Alcohol Intake, Eating Habits, Mental Health and Physical Activity Level.





ITEMS THAT LED RESPONDENTS TO SAY MANAGING THEIR IBS HAS BEEN MORE CHALLENGING INCLUDE:



NEW CONCERNS RESPONDENTS HAVE ABOUT LIVING WITH IBS AFTER THE PANDEMIC INCLUDE:



Respondents were also asked about Paying for visits with my health care provider; Paying for IBS treatment; Losing medical coverage; and, None of these apply to me.



¹ *Pooled IBS-C, CIC, and IBS-D respondents

If you'd like to learn more about this, **ask your health care provider** about the guidelines and available treatment options for IBS at your next in-office or virtual appointment.

Data is from a representative non-probability online sample of U.S. residents, carried out in March, 2021 by Fairleigh Dickinson University's FDU Poll. Participants were recruited based on previously reported gastrointestinal issues. The overall sample size of the survey was 695 respondents, screened to include only those who self-reported having IBS-C/CIC or IBS-D. Respondents were drawn from multiple panels of U.S. residents, and were compensated for their time. Due to the limitations of this survey, results may not be representative of the general IBS population.